Manufacturer
HOE PHARMACEUTICALS SDN. BHD.
Contents
Methadone HCl
Indication
Intractable cough associated with lung cancer
Instruction
Adult: 1-2 mg every 4-6 hr. Reduce to 12 hrly during prolonged use.
Drug interaction
Withdrawal symptoms may be experienced with naloxone, naltrexone, pentazocine, nalbuphine, butorphanol, and buprenorphine. Increased clearance and possible reduced efficacy with some antiretrovirals (abacavir, amprenavir, efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir); rifampin; phenytoin; phenobarbital; carbamazepine. Decreased clearance and possibly increased toxicity with CYP3A4 inhibitors (e.g. ketoconazole, voriconazole, sertraline, fluvoxamine). Increased chance of cardiac toxicity with other QT prolonging drugs. Increased CNS depression with alcohol, other opioids or CNS depressants. Methadone may increase plasma levels of desipramine, zidovudine.